Autopsy report · NCT00312221
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
Cause of deathStaffing, sites or logistics
“terminated early for administrative reasons unrelated to safety or efficacy”
Life of this trial
- Registered 2 years after it had already started.
- Ran for about 1 year 4 months before it stopped.
- 418 participants enrolled.
- Results were posted on the registry 5 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Purdue Pharma LP
- Sponsor type
- Industry
- Conditions
- Osteoarthritis
- Interventions
- Buprenorphine; Buprenorphine; oxycodone immediate-release
- Participants
- 418
- Sites
- 23
- Countries
- United States
Trials that died the same way
- An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
“Terminated early due to a lack of efficacy.” - Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
“Terminated prematurely for administrative reasons not related to patient safety.” - Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
“Terminated due to lack of efficacy” - A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
“Terminated due to safety concerns.” - Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
“Terminated early by Sponsor for business reasons unrelated to safety.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.